Connections BioArctic AB

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 09:27:09 11/03/2026 pm IST			5-day change	1st Jan Change
320.00 ^SEK	-0.25%		+6.88%	+2.96%

03:40pm	BioArctic partner to present long-term lecanemab data at AD/PD conference	FW
20/02	Nordea Raises Price Target for Bioarctic to 240 Kronor (236), Reiterates Sell	FW

13

Listed companies

4

Private companies

29

Insiders

Relation chart of related listed companies: BioArctic AB

Active Relations

Past Relations

Related listed companies: BioArctic AB

GENOVIS AB

Charlotta Ljungqvist

FLERIE INVEST AB

Cecilia Marie Edström

EGETIS THERAPEUTICS AB

Gunilla Christina Osswald

MENDUS AB

Christine Lind

SCANDINAVIAN ENVIRO SYSTEMS AB

Ewa Björling

BACTIGUARD HOLDING AB

Christine Lind

INFANT BACTERIAL THERAPEUTICS AB

Leif Gallo

CINCLUS PHARMA HOLDING AB

Wenche Nelly A. Rolfsen Sandsborg

PROSTATYPE GENOMICS AB

Bengt Håkan Englund

Active Relations

Past Relations

Relationship chart for related private companies: BioArctic AB

Active Relations

Past Relations

Related private companies: BioArctic AB

Karolinska Institutet

Other Consumer Services

Lars Gunnar Lannfelt

Ewa Björling

Spinemedical AB

Medical/Nursing Services

Hans Basun

Gunilla Christina Osswald

Lpb Sweden AB

Real Estate Development

Lars Gunnar Lannfelt

Pär Lars Gellerfors

Gunilla Christina Osswald

A3P Biomedical AB (publ)

Financial Conglomerates

Eugen Steiner

Cecilia Marie Edström

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Pharmaceuticals: Major	5
Medical Specialties	5
Biotechnology	2
Financial Conglomerates	1
Real Estate Development	1
Medical/Nursing Services	1
Other Consumer Services	1
Industrial Specialties	1

Countries of related companies

Sweden

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Employees

131

Sector

Biotechnology & Medical Research

Calendar

20/05 - Earnings release - Q1 2026

More about the company